Literature DB >> 1754610

Misuse of zopiclone and convulsions during withdrawal.

K Aranko1, M Henriksson, C Hublin, A M Seppäläinen.   

Abstract

It has been documented that benzodiazepines have the potential to cause dependence and withdrawal reactions, including convulsions. However, the available data concerning zopiclone, a nonbenzodiazepine hypnotic, are insufficient. The present study describes the case of a 36-year-old man who repeatedly misused zopiclone, in daily doses of 60-90 mg. Furthermore, the patient suffered from convulsion on two occasions following abrupt withdrawal of zopiclone. The concomitant use of alcohol, trimipramine, and promazine may have contributed to the development of convulsions. It is concluded that zopiclone may cause problems associated with misuse and withdrawal reactions similar to those of benzodiazepines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1754610     DOI: 10.1055/s-2007-1014457

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  5 in total

1.  Degradation of zopiclone during storage of spiked and authentic whole blood and matching dried blood spots.

Authors:  Ricarda Jantos; Annemiek Vermeeren; Danica Sabljic; Johannes G Ramaekers; Gisela Skopp
Journal:  Int J Legal Med       Date:  2012-04-25       Impact factor: 2.686

Review 2.  Clinical management of patients with insomnia. The role of zopiclone.

Authors:  G Hajak; A Rodenbeck
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

3.  Zopiclone: is it a pharmacologic agent for abuse?

Authors:  Nevio Cimolai
Journal:  Can Fam Physician       Date:  2007-12       Impact factor: 3.275

Review 4.  Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic.

Authors:  A N Wadworth; D McTavish
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

5.  An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions.

Authors:  Fabrizio Schifano; Stefania Chiappini; John M Corkery; Amira Guirguis
Journal:  Int J Neuropsychopharmacol       Date:  2019-04-01       Impact factor: 5.176

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.